EQ Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals has a net margin of -0.06% compared to Equillium's net margin of -172.04%. Equillium's return on equity of -20.35% beat Madrigal Pharmaceuticals's return on equity of -89.04%.

Equillium has a consensus price target of --, signalling upside risk potential of 416.16%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 19.55%. Given that Equillium has higher upside potential than Madrigal Pharmaceuticals, analysts believe Equillium is more attractive than Madrigal Pharmaceuticals.

Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Equillium quarterly revenues are $12.2M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Equillium's net income of -$7K is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Equillium's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.50x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Matinas BioPharma Holdings has a net margin of -0.06% compared to Equillium's net margin of --. Equillium's return on equity of -20.35% beat Matinas BioPharma Holdings's return on equity of --.

Equillium has a consensus price target of --, signalling upside risk potential of 416.16%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 5560.38%. Given that Matinas BioPharma Holdings has higher upside potential than Equillium, analysts believe Matinas BioPharma Holdings is more attractive than Equillium.

Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.222%.

Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

Equillium quarterly revenues are $12.2M, which are larger than Matinas BioPharma Holdings quarterly revenues of --. Equillium's net income of -$7K is higher than Matinas BioPharma Holdings's net income of -$4.3M. Notably, Equillium's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.50x versus 0.58x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -0.06% compared to Equillium's net margin of -219.3%. Equillium's return on equity of -20.35% beat Spero Therapeutics's return on equity of 4.36%.

Equillium has a consensus price target of --, signalling upside risk potential of 416.16%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 433.33%. Given that Spero Therapeutics has higher upside potential than Equillium, analysts believe Spero Therapeutics is more attractive than Equillium.

Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Equillium quarterly revenues are $12.2M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Equillium's net income of -$7K is higher than Spero Therapeutics's net income of -$17.1M. Notably, Equillium's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 11.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.50x versus 0.56x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Tenon Medical has a net margin of -0.06% compared to Equillium's net margin of -358.96%. Equillium's return on equity of -20.35% beat Tenon Medical's return on equity of -430.31%.

Equillium has a consensus price target of --, signalling upside risk potential of 416.16%. On the other hand Tenon Medical has an analysts' consensus of -- which suggests that it could grow by 349.44%. Given that Equillium has higher upside potential than Tenon Medical, analysts believe Equillium is more attractive than Tenon Medical.

Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Tenon Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tenon Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Tenon Medical pays out -- of its earnings as a dividend.

Equillium quarterly revenues are $12.2M, which are larger than Tenon Medical quarterly revenues of $887K. Equillium's net income of -$7K is higher than Tenon Medical's net income of -$3.2M. Notably, Equillium's price-to-earnings ratio is -- while Tenon Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.50x versus 0.17x for Tenon Medical. Usually stocks with elevated PS ratios are considered overvalued.